^
Association details:
| Biomarker: | MSI-H/dMMR + TMB-H + PD-L1 negative |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | gemcitabine (DNA synthesis inhibitor) + paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer: the case report and literature review
Published date:
08/27/2021
Excerpt:
The 61-year-old male patient was diagnosed with a pancreatic malignancy in our hospital in January 2018... Immune results were PD-L1(-), TMB-H, MMR (p-MMR), MSI (microsatellite stable)...Postoperative paclitaxel plus gemcitabine were selected as the adjuvant chemotherapy regimen. Four courses of chemotherapy were performed from 30 January 2018 to 1 March 2018. Unfortunately, the patient developed disease progression in June 2018...
DOI:
10.1097/CAD.0000000000001232
